"I will remain in an advisory role. My strong commitment to the company will continue and I will closely follow its further development", comments Masoud Khayyami.
"I would like to thank Masoud Khayyami for his dedicated long engagement in the company. He has during more than a decade devoted his life to SpectraCure as a board member", says Ingemar Kihlström.
The nomination committee has decided to propose Dr. Homer Pien as new member of the Board.
"I am very pleased that Homer Pien, most recently Senior Vice President and Chief Scientific Officer of Philips’ Precision Diagnosis cluster of businesses, has accepted the nomination to the Board of SpectraCure", says Ingemar Kihlström.
"I am honored and excited to be nominated as a Board member. Photodynamic therapy holds tremendous potential for localized and precise treatment of certain types of cancers, and I am delighted to join and support SpectraCure on its journey to add yet another weapon in the fight against cancer", comments Homer Pien.
Dr. Homer Pien recently retired from Philips having held various positions including CSO as well as Chief Technology Officer of the Imaging System business. Prior to Philips, Homer Pien was with Massachusetts General Hospital and Harvard Medical School for nine years. He has also held roles with various start-up companies and research labs in the U.S, and he has a PhD in Computer Science, and a MS in Management of Technology.
A presentation of current board members is available on the SpectraCure’s website, www.spectracure.com. SpectraCure’s Nomination Committee for the 2021 Annual General Meeting includes Fredrik Nilsson, representing his own holding and related parties' holdings, Dan Persson, representing his own holding and finally Jan Karlsson, representing his own holding.
For further information, please contact:
The Chairman of the Nomination Committee, Fredrik Nilsson, ph + 46 733 172 883.
SpectraCure focuses on cancer treatments with medical systems based on laser light sources, connected to the tumour by way of optical fibers, in combination with a photoreactive drug. The method is referred to as Interstitial Photodynamic Therapy, PDT. The treatment is suitable for internal solid tumours of various kind, such as prostate and pancreatic tumours, but also for example for cancers of the head and neck. www.spectracure.com.
The Company is listed in the Premier segment at Nasdaq First North Growth Market with G&W Fondkommission as the Company’s Certified Adviser, email@example.com, ph. +46(0) 8 503 00 050. The share is traded under the ticker SPEC.